Drug Trial Radar · NCT06798675
Phase 2a Study for PK/PD of nC-001
Last checked: Nov 19, 2026Latest source record: May 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Aug 2025
Primary completion
Mar 2026
Study completion Jun 2026
Sponsor
- Lead sponsor
- nephCentricIndustry
- Sponsor type
- Industry
- First posted
- Jan 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
CHRONIC EUVOLEMIC HYPONATREMIA
Conditions
- CHRONIC HYPONATREMIA
Interventions
nC-001Drug
solid dosage form single dose
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Serum Urea and Sodium (Na)Time frame: 24 hrs
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.